BR112015027587A2 - Anticorpos anti-vegf e uso dos mesmos - Google Patents
Anticorpos anti-vegf e uso dos mesmosInfo
- Publication number
- BR112015027587A2 BR112015027587A2 BR112015027587A BR112015027587A BR112015027587A2 BR 112015027587 A2 BR112015027587 A2 BR 112015027587A2 BR 112015027587 A BR112015027587 A BR 112015027587A BR 112015027587 A BR112015027587 A BR 112015027587A BR 112015027587 A2 BR112015027587 A2 BR 112015027587A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- sequence selected
- vegf
- antibodies
- chain variable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
ANTICORPOS ANTI-VEGF E USO DOS MESMOS. Um anticorpo anti-VEGF, ou um seu fragmento de ligação, inclui uma região variável de cadeia pesada que compreende: (i) uma sequência de CDRH1 selecionada a partir de SEQ ID NO: 17, 20, 23, 26, 29, 32, 35, ou 38, (2) uma sequência de CDRH2 selecionada a partir de SEQ ID NO: 18, 21, 24, 27, 30, 33, 36, ou 39, e (3) uma sequência de CDRH3 selecionada a partir da SEQ ID NO: 19, 22, 25, 28, 31, 34, 37, ou 40; e uma região variável de cadeia leve que compreende: (i) uma sequência de CDRL1 selecionada a partir de SEQ ID NO: 41, 44, 47, 50, 53, 56, 59, ou 62, (2) um sequência de CDRL2 selecionada a partir de SEQ ID NO: 42, 45, 48, 51, 54, 57, 60, ou 63, e (3) uma sequência de CDRL3 selecionada a partir de SEQ ID NO: 43, 46, 49, 52, 55, 58, 61, ou 64. Um método para o tratamento ou prevenção de um distúrbio relacionado com o VEGF, por exemplo, retinopatia diabética, degeneração macular relacionada com a idade, ou câncer, utiliza os anticorpos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361922537P | 2013-12-31 | 2013-12-31 | |
| PCT/US2014/072557 WO2015103139A1 (en) | 2013-12-31 | 2014-12-29 | Anti-vegf antibodies and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015027587A2 true BR112015027587A2 (pt) | 2017-09-19 |
Family
ID=53493951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015027587A BR112015027587A2 (pt) | 2013-12-31 | 2014-12-29 | Anticorpos anti-vegf e uso dos mesmos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160130336A1 (pt) |
| EP (1) | EP3089993A1 (pt) |
| JP (1) | JP2016530244A (pt) |
| KR (1) | KR20150132581A (pt) |
| CN (1) | CN105263959A (pt) |
| BR (1) | BR112015027587A2 (pt) |
| MX (1) | MX2015014724A (pt) |
| TW (1) | TW201524998A (pt) |
| WO (1) | WO2015103139A1 (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| JP6572131B2 (ja) | 2012-12-12 | 2019-09-04 | バスキュロックス インコーポレイテッド | 治療用ｃｄ４７抗体 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| UA126146C2 (uk) | 2015-09-18 | 2022-08-25 | Арч Онколоджі, Інк. | Терапевтичне антитіло до cd47 |
| AR106184A1 (es) | 2015-09-29 | 2017-12-20 | Celgene Corp | Proteínas de unión a pd-1 y sus métodos de uso |
| AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| US20170233480A1 (en) * | 2015-12-31 | 2017-08-17 | Development Center For Biotechnology | Anti-vegfr antibody and uses thereof |
| KR102257154B1 (ko) | 2016-09-19 | 2021-05-28 | 셀진 코포레이션 | Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법 |
| WO2018053401A1 (en) | 2016-09-19 | 2018-03-22 | Celgene Corporation | Methods of treating vitiligo using pd-1 binding proteins |
| EP3529276A4 (en) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | CD47 THERAPEUTIC ANTIBODIES |
| JP2020512359A (ja) * | 2017-03-29 | 2020-04-23 | セルジーン コーポレイション | Ｐｄ−１結合タンパク質を含む製剤及びそれを作製する方法 |
| CN110790837A (zh) * | 2018-08-02 | 2020-02-14 | 上海君实生物医药科技股份有限公司 | 抗btla抗体 |
| CN111349142A (zh) * | 2018-12-20 | 2020-06-30 | 上海百迈博制药有限公司 | 一种蛋白质的纯化方法 |
| JP2022553640A (ja) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | 眼障害を処置する方法 |
| CN114349853B (zh) * | 2022-01-13 | 2024-06-11 | 浙江大学医学院附属第一医院 | 抗h1n1流感病毒血凝素蛋白中和性单克隆抗体zju11-01及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2273415T3 (es) * | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
| CA2406993A1 (en) * | 2000-03-24 | 2001-09-27 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| US7667004B2 (en) * | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| JP2007513976A (ja) * | 2003-12-15 | 2007-05-31 | デンドレオン コーポレイション | Ｈｌａ−ｄｒ特異的抗体、組成物、および方法 |
| ES2457072T3 (es) * | 2006-08-14 | 2014-04-24 | Xencor, Inc. | Anticuerpos optimizados que seleccionan como diana CD19 |
| US20110076279A1 (en) * | 2006-10-20 | 2011-03-31 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| AR069501A1 (es) * | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
| CN103992405B (zh) * | 2008-03-26 | 2016-08-17 | 宜康公司 | 抗-vegf抗体 |
| CN102439138B (zh) * | 2009-03-13 | 2018-03-30 | 阿勒根公司 | 可用于基于免疫的肉毒杆菌毒素血清a型活性测定的细胞 |
| BR112013013003A2 (pt) * | 2010-11-24 | 2016-08-09 | Glaxo Group Ltd | proteína de ligação de antígeno, e, composição farmacêutica |
-
2014
- 2014-12-29 MX MX2015014724A patent/MX2015014724A/es unknown
- 2014-12-29 KR KR1020157030378A patent/KR20150132581A/ko not_active Application Discontinuation
- 2014-12-29 BR BR112015027587A patent/BR112015027587A2/pt not_active Application Discontinuation
- 2014-12-29 WO PCT/US2014/072557 patent/WO2015103139A1/en active Application Filing
- 2014-12-29 TW TW103146069A patent/TW201524998A/zh unknown
- 2014-12-29 US US14/895,297 patent/US20160130336A1/en not_active Abandoned
- 2014-12-29 EP EP14877159.5A patent/EP3089993A1/en not_active Withdrawn
- 2014-12-29 CN CN201480025494.7A patent/CN105263959A/zh active Pending
- 2014-12-29 JP JP2016527159A patent/JP2016530244A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016530244A (ja) | 2016-09-29 |
| TW201524998A (zh) | 2015-07-01 |
| US20160130336A1 (en) | 2016-05-12 |
| CN105263959A (zh) | 2016-01-20 |
| EP3089993A1 (en) | 2016-11-09 |
| MX2015014724A (es) | 2016-06-02 |
| KR20150132581A (ko) | 2015-11-25 |
| WO2015103139A1 (en) | 2015-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015027587A2 (pt) | Anticorpos anti-vegf e uso dos mesmos | |
| CL2021000458A1 (es) | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr (divisional de solicitud 201602359) | |
| PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
| PE20161033A1 (es) | Proteinas de union al antigeno gitr | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| BR112014027291A2 (pt) | composições de anticorpos pan-her humanizados | |
| ES2631135T3 (es) | Proteínas de unión a antígeno humanas que se unen a beta-Klotho, receptores de FGF y complejos de los mismos | |
| BR112017003194B8 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| PE20171244A1 (es) | Anticuerpos contra el inmunorreceptor de celulas t con dominios de inmunoglobulina y de porcion inhibidora con base en tirosina del inmunorreceptor (tigit) | |
| AR102554A1 (es) | Receptores quiméricos de antígeno anti-cldn y métodos de uso | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| RS54627B1 (en) | CANCER EXPRESSION ANTIBODIES THAT EXPLAIN CLAUDINE 6 | |
| ES2430068T3 (es) | Proteínas de unión a antígeno del factor de crecimiento de tipo factor de crecimiento epidérmico de unión a heparina | |
| NZ706377A (en) | Il-6 antagonists and uses thereof | |
| EA033072B1 (ru) | Применение антител к семафорину 4d для лечения болезни хантингтона | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| BR112012026934A2 (pt) | processo para a preparação de uma composição, preparação de anticorpo, composição de imunoglobulina contendo igm, uso de uma preparação de anticorpo, e, método de tratamento de um paciente | |
| NZ623347A (en) | Novel anti-dr5 antibody | |
| CY1121158T1 (el) | Αντισωμα ικανο να αναγνωριζει ειδικα υποδοχεα τρανσφερρινης | |
| UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
| RS52345B (en) | ANTI-IL-23P19 ANTIBODY MANUFACTURED BY GENETIC ENGINEERING | |
| PE20141659A1 (es) | Dominios variables singulares anti-vgf fusionados con dominios de fc |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |